RT Journal Article
T1 SILAC-based nuclear proteomics uncovers antitumor mechanisms of selenium nanoparticles with in vivo validation in a melanoma model
A1 García Calvo, Estefanía
A1 Estévez Sánchez, Héctor
A1 Álvarez-Fernández García, Roberto
A1 Sánchez-Díaz, Raquel
A1 Lazcano, Juan José
A1 Martín, Pilar
A1 Luque García, José Luis
AB Chitosan-stabilized selenium nanoparticles (Ch-SeNPs) are promising agents for cancer therapy due to their unique physicochemical properties, including spherical morphology and uniform size distribution. This study investigates the molecular mechanisms underlying their antitumoral effects, with a focus on the nuclear proteome. Quantitative proteomic analysis revealed 343 nuclear proteins, 47 of which showed significant changes following Ch-SeNPs treatment. Key regulators such as CDK1 and CDC5 were implicated in cell cycle arrest and tumor suppression pathways. Ch-SeNPs also affected processes including mRNA metabolism and cytoskeleton organization. In addition, Ch-SeNPs significantly inhibited tumor growth in a murine melanoma model, supporting their therapeutic potential.
PB Elsevier
YR 2025
FD 2025-06-06
LK https://hdl.handle.net/20.500.14352/121630
UL https://hdl.handle.net/20.500.14352/121630
LA eng
NO Estevez H, Garcia-Calvo E, Álvarez-Fernández Garcia R, Sanchez-Diaz R, Lazcano JJ, Martin P, Luque-Garcia JL. SILAC-based nuclear proteomics uncovers antitumor mechanisms of selenium nanoparticles with in vivo validation in a melanoma model. Journal of Drug Delivery Science and Technology 2025; 111: 107155. [DOI: 10.1016/j.jddst.2025.107155]
NO This work was supported by Ministerio de Ciencia, Innovacion y Universidades (MICIU) grants PID2020-114529RB-I00 and PID2023- 150182OB-I00. PM is supported by grants from the Madrid Regional Government (S2022/BMD-7209-INTEGRAMUNE-CM), MCIN-ISCIIIFondo de Investigacion ´ Sanitaria (PI22/01759). Hector Estevez acknowledges Ministry of Science, Innovation and Universities from the Spanish Government for a pre-doctoral fellowship (PRE2018-084196
NO Ministerio de Ciencia, Innovacion y Universidades (España)
NO Comunidad de Madrid
DS Docta Complutense
RD 1 ene 2026